Business Description
LungLife AI Inc
NAICS : 621512
SIC : 2835
ISIN : USU5500L1045
Description
LungLife AI Inc is focused on a developing clinical diagnostic solutions for lung cancer. The Company generates revenue from People's Republic of China and also has its presence in the United States of America.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.4 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -13.93 | |||||
| Beneish M-Score | -2.13 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -45 | |||||
| 3-Year EBITDA Growth Rate | -12.8 | |||||
| 3-Year EPS without NRI Growth Rate | -8.9 | |||||
| 3-Year FCF Growth Rate | -23.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.79 | |||||
| 9-Day RSI | 23.44 | |||||
| 14-Day RSI | 27.99 | |||||
| 3-1 Month Momentum % | 61.62 | |||||
| 6-1 Month Momentum % | 7.38 | |||||
| 12-1 Month Momentum % | -65.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.83 | |||||
| Quick Ratio | 2.83 | |||||
| Cash Ratio | 2.5 | |||||
| Days Sales Outstanding | 3142.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -282.28 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -16347.83 | |||||
| Net Margin % | -15313.04 | |||||
| FCF Margin % | -14829.63 | |||||
| ROE % | -50.88 | |||||
| ROA % | -43.59 | |||||
| ROIC % | -66.88 | |||||
| 3-Year ROIIC % | 62.08 | |||||
| ROC (Joel Greenblatt) % | -1211.45 | |||||
| ROCE % | -49.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 3.88 | |||||
| PS Ratio | 14 | |||||
| PB Ratio | 0.07 | |||||
| Price-to-Tangible-Book | 0.26 | |||||
| EV-to-EBIT | 0.42 | |||||
| EV-to-Forward-EBIT | -0.35 | |||||
| EV-to-EBITDA | 0.45 | |||||
| EV-to-Forward-EBITDA | -0.38 | |||||
| EV-to-Revenue | -64.43 | |||||
| EV-to-Forward-Revenue | 0.14 | |||||
| EV-to-FCF | 0.43 | |||||
| Price-to-GF-Value | 0.06 | |||||
| Price-to-Net-Current-Asset-Value | 0.26 | |||||
| Price-to-Net-Cash | 0.39 | |||||
| Earnings Yield (Greenblatt) % | 238.1 | |||||
| FCF Yield % | -797.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LungLife AI Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.027 | ||
| EPS (TTM) (€) | -0.15 | ||
| Beta | 1.73 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.89 | ||
| Volatility % | 88.27 | ||
| 14-Day RSI | 27.99 | ||
| 14-Day ATR (€) | 0.005479 | ||
| 20-Day SMA (€) | 0.023625 | ||
| 12-1 Month Momentum % | -65.52 | ||
| 52-Week Range (€) | 0.0155 - 0.454 | ||
| Shares Outstanding (Mil) | 30.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LungLife AI Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LungLife AI Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
LungLife AI Inc Frequently Asked Questions
What is LungLife AI Inc(FRA:9H4)'s stock price today?
The current price of FRA:9H4 is €0.02. The 52 week high of FRA:9H4 is €0.45 and 52 week low is €0.02.
When is next earnings date of LungLife AI Inc(FRA:9H4)?
The next earnings date of LungLife AI Inc(FRA:9H4) is 2025-04-04 Est..
Does LungLife AI Inc(FRA:9H4) pay dividends? If so, how much?
LungLife AI Inc(FRA:9H4) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers